UGGC Avocats continues to grow and welcomes Xavier Marchand and Alison Leroy as partners
Paris, July 5, 2024 – UGGC Avocats is delighted to announce the arrival of two new partners to its team: Xavier Marchand and Alison Leroy.
Homburger advised AMAG Leasing AG on the CHF 100 m Auto Covered Bond Issuance
On July 10, 2024, AMAG Leasing successfully completed its issuance of CHF 100 m 1.700 per cent.
S&R Associates Welcomes New Partner
We are pleased to announce that Aakanksha Joshi will join S&R Associates on August 19, 2024, as a retained partner in the Firm’s Mumbai office.
“Tier 1” in All 17 Practice Areas – The Legal 500 Asia Pacific 2024
In the 2024 edition of The Legal 500 Asia Pacific, Kim & Chang was the only Korean law firm to be recognized as “Tier 1” in all 17 areas surveyed for Korea.
Ranked “Band 1” in All Nine Areas, 39 “Leading Individuals” Recognized – Chambers Global 2024
In the 2024 edition of Chambers Global, Kim & Chang was once again the only Korean law firm ranked “Band 1” in all nine practice areas that were surveyed for Korea.
“Jurisdictional Firm of the Year: South Korea” – IFLR Asia-Pacific Awards 2024
Kim & Chang was awarded the “Jurisdictional Firm of the Year: South Korea” recognition at the IFLR Asia-Pacific Awards 2024.
Argus Partners advises Whiteboard Capital on its stake sale in Dezerv to Premji Invest, Elevation Capital, Matrix Partners (aka Z47) and Accel
We are pleased to share that Argus Partners has advised Whiteboard Capital in relation to its stake sale in Dezerv Investments Private Limited (“Dezerv”) to Premji Invest, Elevation Capital, Matrix Partners (aka Z47) and Accel.
E+H appoints new partner from its own ranks
E+H is pleased to announce that Arndt Blaschka has been appointed as a new partner of the firm with immediate effect.
Homburger advises DALI DISCOUNT AG in connection with its Series C financing round and its previous financing round
Swiss-based DALI DISCOUNT AG, a leading hard discounter in Southeast Asia, has received multiple equity financings as part of its Series C financing round and its previous financing round from Navegar,
E+H advises Ligand on acquisition of APERION Biologics
E+H advises Ligand Pharmaceuticals Incorporated on the planned acquisition of all shares in the Austrian stock corporation APEIRON Biologics AG.